RNA

RNA is trading as a high-conviction 'Special Situation' arbitrage, currently priced at $72.86—a premium to the $72.00 Novartis acquisition offer—reflecting the embedded value of the imminent cardiology 'SpinCo' distribution. The 'Quiet Storm' and 'Perfect Stack' signals confirm the stock is effectively pegged to the deal terms, insulating it from the broader 'Geopolitical Caution' macro regime. Today's NEJM publication of the MARINA trial data serves as a critical 'quality check,' validating the underlying platform and supporting the valuation of the SpinCo stub ahead of the H1 2026 deal close.